MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX)

Historical Holders from Q1 2022 to Q4 2025

Symbol
MLTX on Nasdaq
Type / Class
Equity / Class A Ordinary Shares, par value $0.0001 per share
Shares outstanding
63,492,063
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
37,454,837
Holdings value
$268,355,894
% of all portfolios
0%
Number of holders
132
Number of buys
78
Number of sells
86
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 28% $141,616,706 19,751,284 BVF PARTNERS L P/IL 06 Nov 2025
Deep Track Capital, LP 6.5% $33,054,209 4,610,071 Deep Track Capital, LP 05 Nov 2025
PRICE T ROWE ASSOCIATES INC /MD/ 4.7% -12% $117,334,991 -$14,571,725 2,974,271 -11% T. Rowe Price Associates, Inc. 31 Mar 2025
Avoro Capital Advisors LLC 3.2% -48% $14,340,000 -$15,415,500 2,000,000 -52% Avoro Capital Advisors LLC 30 Sep 2025
Chen Bihua 3.1% $108,084,177 1,994,173 Chen Bihua 30 Sep 2025
FMR LLC 1.1% -88% $5,212,098 -$35,678,759 726,931 -87% FMR LLC 30 Sep 2025
As of 30 Sep 2025 MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 132 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 37,454,837 shares of 63,492,063 outstanding shares and own 59% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) own 54% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BVF INC/IL 31% 19,751,284 0% 5.7% $141,616,706
Avoro Capital Advisors LLC 3.2% 2,000,000 -52% 0.19% $14,340,000
Cormorant Asset Management, LP 3.1% 1,994,173 -77% 0.99% $14,298,220
Balyasny Asset Management L.P. 2.7% 1,699,235 +302% 0.02% $12,183,515
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.4% 1,500,000 0.02% $10,755,000
Schonfeld Strategic Advisors LLC 1.5% 965,405 0.05% $6,921,951
PRICE T ROWE ASSOCIATES INC /MD/ 1.3% 822,957 -69% 0% $5,901,000
FMR LLC 1.1% 726,932 -87% 0% $5,212,098
Nuveen, LLC 1% 635,699 -20% 0% $4,557,962
TWO SIGMA INVESTMENTS, LP 0.72% 454,268 0.01% $3,257,102
Ikarian Capital, LLC 0.69% 435,839 0.71% $3,124,965
GOLDMAN SACHS GROUP INC 0.57% 362,871 -72% 0% $2,601,785
MARSHALL WACE, LLP 0.51% 321,109 -39% 0% $2,302,353
Verition Fund Management LLC 0.43% 272,768 +1059% 0.01% $1,955,747
First Turn Management, LLC 0.41% 262,643 0.28% $1,883,150
BOOTHBAY FUND MANAGEMENT, LLC 0.41% 258,779 0.05% $1,855,445
MORGAN STANLEY 0.4% 256,655 +494% 0% $1,840,218
Boxer Capital Management, LLC 0.39% 250,000 0.57% $1,792,500
Rhenman & Partners Asset Management AB 0.33% 207,000 +360% 0.16% $1,484,190
SCHRODER INVESTMENT MANAGEMENT GROUP 0.31% 195,490 +908% 0% $1,220,835
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.31% 194,741 0% $1,396,293
Exome Asset Management LLC 0.28% 178,084 0.87% $1,276,862
JPMORGAN CHASE & CO 0.27% 174,161 +342% 0% $1,248,734
ADAR1 Capital Management, LLC 0.24% 151,495 +341% 0.11% $1,086,219
HRT FINANCIAL LP 0.23% 143,275 0% $1,027,000

Institutional Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 0 $0 -$43 0
2025 Q3 37,454,837 $268,355,894 -$543,765,843 $7.17 132
2025 Q2 58,588,386 $2,765,378,029 -$36,637,296 $47.20 129
2025 Q1 59,723,013 $2,333,397,891 -$153,122,113 $39.07 134
2024 Q4 63,244,825 $3,424,722,298 +$68,390,992 $54.15 114
2024 Q3 62,105,859 $3,131,140,770 +$81,133,174 $50.42 108
2024 Q2 60,656,094 $2,667,012,692 +$45,095,266 $43.97 109
2024 Q1 59,346,206 $2,980,958,004 +$1,466,170 $50.23 112
2023 Q4 58,433,271 $3,528,831,635 +$147,969,282 $60.39 124
2023 Q3 56,323,727 $3,210,450,399 +$46,563,145 $57.00 118
2023 Q2 56,057,516 $2,858,934,462 +$861,230,424 $51.00 82
2023 Q1 39,419,149 $843,176,754 +$59,244,738 $21.39 43
2022 Q4 37,748,780 $396,358,589 +$8,234,061 $10.50 32
2022 Q3 36,855,847 $291,356,995 +$3,123,162 $7.76 24
2022 Q2 36,470,008 $190,106,000 +$182,848,000 $5.25 22
2022 Q1 653,872 $7,258,000 +$7,258,000 $11.10 1